CDC Issues Updated RSV Vaccine Guidance for Adults 60 and Older

ACIP Updates RSV Vaccine Recommendations for Older Adults

On June 26, 2024, the Advisory Committee on Immunization Practices recommended a single dose of any approved RSV vaccine for all adults aged 75 years and older. Adults aged 60 to 74 years qualify for the vaccine only if they have increased risk for severe RSV disease, such as chronic heart or lung disease, diabetes, or immunocompromising conditions. The update drops routine consideration for adults 60 to 74 years without those risk factors. It refines the 2023 approach that applied shared clinical decision-making to all adults aged 60 and older. The report found that early real-world evidence from the prior season, combined with clinical trial data, supported this risk-based refinement. [1][2]

What this means

The updated guidance narrows the eligible pool compared with last year. It sets a clear line at age 75 for universal recommendation while tying the 60-to-74 group to specific health factors. Data suggest the highest benefit appears among those with underlying cardiopulmonary disease, diabetes, or weakened immune systems. Real-world uptake last season stayed low, which shaped this more targeted stance.

Key takeaways

• All adults aged 75 years and older qualify for a single dose of RSV vaccine under the 2024 guidance [1].
• Adults 60–74 years qualify only if they have increased risk for severe RSV, including chronic heart or lung disease, diabetes, or immunocompromising conditions [1].
• The three approved vaccines are Arexvy (GSK), Abrysvo (Pfizer), and mResvia (Moderna) [1].
• Revaccination is not recommended at this time [3].
• The update draws on evidence that all three vaccines showed efficacy against RSV-associated lower respiratory tract disease in adults 60 and older [2].

Updated recommendations in detail

The CDC aligned with ACIP’s June 2024 vote. Universal recommendation now covers every adult 75 or older. The risk-based track for ages 60 to 74 lists clear examples like heart failure, COPD, diabetes requiring medication, or conditions that suppress immunity. Those without such factors no longer receive a routine suggestion.

How 2024 differs from 2023

The 2023 guidance used shared clinical decision-making for all adults 60 and older. The 2024 version removes that step for adults 60 to 74 years without documented risk factors. Officials cited early season uptake data and clearer risk patterns to support the tighter focus [1][2].

Vaccines covered

Three products meet the CDC’s updated criteria. Arexvy from GSK, Abrysvo from Pfizer, and mResvia from Moderna all demonstrated protection against lower respiratory tract disease in the key trials. Clinicians may choose any of the three for eligible adults [1].

Safety and monitoring notes

All three vaccines carry signals for rare but serious adverse events, including Guillain-Barré syndrome. Post-licensure monitoring continues. The current evidence does not yet extend far beyond one season for most real-world measures [1].

Limitations

Real-world effectiveness and duration of protection data are still limited beyond one season. Vaccine coverage in the first season was low, limiting some effectiveness estimates. Certain risk factors for severe RSV have not been fully quantified in all populations. Recommendations may be revised as additional post-marketing safety and effectiveness data accrue [1][3].

Frequently Asked Questions

Which specific age and risk groups qualify for RSV vaccination under the 2024 update?
All adults aged 75 years and older. Adults 60–74 years qualify if they have increased risk for severe RSV, such as chronic heart or lung disease, diabetes, or immunocompromise [1].

What are the three FDA-approved RSV vaccines covered by the CDC recommendation?
Arexvy (GSK), Abrysvo (Pfizer), and mResvia (Moderna) [1].

How does the 2024 guidance differ from the 2023 ACIP recommendations?
The 2023 version used shared clinical decision-making for all adults 60 and older. The 2024 update sets universal recommendation at age 75 and risk-based recommendation for ages 60–74, dropping routine consideration for lower-risk adults in that range [2].

What safety and effectiveness data informed the updated risk-based approach?
Early real-world evidence from the 2023–2024 season, combined with clinical trial data showing efficacy against lower respiratory tract disease and recognition that benefit concentrates in those with underlying conditions [1][2].